Circulating Prostate Cancer Progenitor Cell Assay Development

Award Information
Agency:
Department of Defense
Branch
Army
Amount:
$96,765.00
Award Year:
2008
Program:
STTR
Phase:
Phase I
Contract:
W81XWH-08-C-0099
Agency Tracking Number:
A08A-041-0388
Solicitation Year:
2008
Solicitation Topic Code:
A08-T041
Solicitation Number:
2008.A
Small Business Information
ANDROBIOSYS, INC.
73 High Street, Buffalo, NY, 14203
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
193493157
Principal Investigator:
Michael Zwick
CEO
(716) 860-7920
mzwick@androbiosys.com
Business Contact:
Michael Zwick
CEO
(716) 860-7920
mzwick@androbiosys.com
Research Institution:
ROSWELL PARK CANCER INSTITUTE
Joseph H Jurkowski
Elm and Carlton Streets
Buffalo, NY, 14263
(716) 845-2312
Domestic nonprofit research organization
Abstract
This Phase I contract proposal will evaluate and identify markers associated with prostate cancer progenitor stem cells, that differentiate these cells from adult tissue stem cells and benign prostate progenitor cells. The eventual goal of this work would be to develop a high throughput blood-based assay highly specific for circulating prostate cancer progenitor cells. A cell shed from a tumor must be capable of surviving separate from the microenvironment of the primary tumor, and possess the capacities of proliferation and plasticity, to regenerate a metastasis. These traits essentially describe a cancer stem cell (CSC). Therefore, we propose to develop a technology to identify circulating CSCs, or more accurately the progenitor cells that are their immediate progeny, an approach that should provide a more informative prognostic tool for prediction of aggressiveness and metastatic potential.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government